Relmada Therapeutics, Inc. RLMD
Institutional shares held
7.88 Million
84.3K
calls
0
puts
Total value of holdings
$31.1M
$332K
calls
$0
puts
Market Cap
$113M
28,608,500
Shares Out.
Institutional ownership
27.53%
# of Institutions
51
We take great care to ensure that the data presented and summarized in this overview for RELMADA THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RLMD
View all-
Ikarian Capital, LLC Dallas, TX1.84MShares$7.28 Million0.58% of portfolio
-
Driehaus Capital Management LLC Chicago, IL740KShares$2.92 Million0.01% of portfolio
-
Boothbay Fund Management, LLC New York, NY693KShares$2.74 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA583KShares$2.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$2.26 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA419KShares$1.65 Million0.0% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD403KShares$1.59 Million0.15% of portfolio
-
Geode Capital Management, LLC Boston, MA296KShares$1.17 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0272KShares$1.07 Million0.0% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M225KShares$888,1410.0% of portfolio
Latest Institutional Activity in RLMD
Top Purchases
Top Sells
About RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Insider Transactions at RLMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2025
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
11,665
+1.44%
|
$46,660
$4.12 P/Share
|
|
Dec 15
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
27,500
+2.07%
|
$110,000
$4.12 P/Share
|
|
Nov 05
2025
|
Paul Edward Kelly COO |
BUY
Open market or private purchase
|
Direct |
90,000
+15.2%
|
$180,000
$2.2 P/Share
|
|
Nov 05
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
272,500
+17.64%
|
$545,000
$2.2 P/Share
|
|
Nov 05
2025
|
Chuck Ence CA and CO |
BUY
Open market or private purchase
|
Direct |
136,000
+25.19%
|
$272,000
$2.2 P/Share
|
|
Nov 05
2025
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
500,000
+38.81%
|
$1,000,000
$2.2 P/Share
|
|
Aug 28
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
55,976
+5.3%
|
$0
$0.74 P/Share
|
|
Aug 27
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
129,455
+12.06%
|
$0
$0.67 P/Share
|
|
Aug 26
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
80,545
+9.0%
|
$0
$0.62 P/Share
|
|
May 20
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
147,686
+16.75%
|
$0
$0.56 P/Share
|
|
May 20
2025
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
60,000
+17.22%
|
$0
$0.52 P/Share
|
|
May 19
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+4.87%
|
$0
$0.5 P/Share
|
|
May 19
2025
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
90,000
+28.27%
|
$0
$0.49 P/Share
|
|
May 16
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
172,314
+23.65%
|
$0
$0.45 P/Share
|
|
May 16
2025
|
Chuck Ence CA and CO |
BUY
Open market or private purchase
|
Direct |
228,961
+46.08%
|
$0
$0.45 P/Share
|
|
May 16
2025
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+26.55%
|
$0
$0.44 P/Share
|
|
May 16
2025
|
Paul Edward Kelly COO |
BUY
Open market or private purchase
|
Direct |
200,000
+32.66%
|
$0
$0.43 P/Share
|
|
Oct 22
2024
|
Charles J Casamento Director |
SELL
Bona fide gift
|
Direct |
13,000
-100.0%
|
-
|
|
Sep 11
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
24,120
+21.45%
|
$48,240
$2.95 P/Share
|
|
Sep 11
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
51,407
+11.81%
|
$102,814
$2.99 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.28M
Shares
From
4
Insiders
| Open market or private purchase | 2.28M shares |
|---|
Sell / Disposition
0
Shares
From
0
Insiders